Surfing the MASH Tsunami

Surfing the MASH Tsunami

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL

Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(1073)

S3-E11.2 - NAIL-NIT and the Challenges of Histopathology

S3-E11.2 - NAIL-NIT and the Challenges of Histopathology

Send us Fan Mail NAIL-NIT is both a response to the challenges of histopathology and an effort to create a different vision of testing liver patients. This episode starts with Stephen Harrison descri...

19 Feb 202212min

S3-E11.1 - NAIL-NIT: The Thinking Behind a New NAFLD Consortium

S3-E11.1 - NAIL-NIT: The Thinking Behind a New NAFLD Consortium

Send us Fan Mail NAIL-NIT is a new NAFLD consortium dedicated to exploring the direct relationship between non-invasive testing (NITs) and outcomes in Fatty Liver disease. In this opening conversation...

19 Feb 202215min

S3-E11 - NAIL-NIT and the Path from Non-Invasive Testing To Outcomes

S3-E11 - NAIL-NIT and the Path from Non-Invasive Testing To Outcomes

Send us Fan Mail Co-director Mazen Noureddin and Steering Committee members Amy Articolo of Novo Nordisk and Senthil Sundaram of Terns Pharmaceuticals join the Surfers (Stephen Harrison is also a co-d...

17 Feb 20221h 1min

S3-E10.4 - Value of Screening for NAFLD as NASH Prevalence Grows

S3-E10.4 - Value of Screening for NAFLD as NASH Prevalence Grows

Send us Fan Mail Episode 10 dives into recent NAFLD and NASH Prevalence studies in the US, UK and Germany and explores what this can tell us about who to screen for NAFLD and NASH, when to screen firs...

13 Feb 202215min

S3-E10.3 - Value of Early NASH Diagnosis as NAFLD Prevalence Grows

S3-E10.3 - Value of Early NASH Diagnosis as NAFLD Prevalence Grows

Send us Fan Mail Episode 10 dives into recent NAFLD and NASH Prevalence studies in the US, UK and Germany and explores what this can tell us about who to screen for NAFLD and NASH, when to screen firs...

13 Feb 202212min

S3-E10.2 - What Does the SUNN Study Say About NASH Prevalence?

S3-E10.2 - What Does the SUNN Study Say About NASH Prevalence?

Send us Fan Mail Episode 10 dives into recent NAFLD and NASH Prevalence studies in the US, UK and Germany and explores what this can tell us about who to screen for NAFLD and NASH, when to screen firs...

12 Feb 202212min

S3-E10.1 - NAFLD and NASH Prevalence and Advanced Liver Fibrosis in Germany

S3-E10.1 - NAFLD and NASH Prevalence and Advanced Liver Fibrosis in Germany

Send us Fan Mail Episode 10 dives into recent NAFLD and NASH Prevalence studies in the US, UK and Germany and explores what this can tell us about who to screen for NAFLD and NASH, when to screen firs...

12 Feb 202215min

S3-E10 - Screening and Treatment Pathways in a World with High NAFLD Prevalence

S3-E10 - Screening and Treatment Pathways in a World with High NAFLD Prevalence

Send us Fan Mail This episode looks at four different sources of data estimating NASH and NAFLD prevalence in population subgroups the US, UK and Germany. All four suggest that the share of people liv...

10 Feb 20221h 1min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
liberal-halvtime
forskningno
rekommandert
jss
sinnsyn
abels-tarn
villmarksliv
dekodet-2
fjellsportpodden
rss-nysgjerrige-norge
tomprat-med-gunnar-tjomlid
hva-er-greia-med
mer-enn-hjerne
rss-inn-til-kjernen-med-sunniva-rose
kvinnehelsepodden
rss-rekommandert
diagnose
grunnstoffene